3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Neuroendocrine Tumors
12
Meningioma
5
Prostatic Neoplasms
2
Pheochromocytoma
2
Paraganglioma
2
Neuroblastoma
2
Medulloblastoma
2
Glioma
2
Glioblastoma
2
Ependymoma
2
Carcinoma, Merkel Cell
2
Sarcoma, Synovial
1
Recurrence
1
Pancreatic Neoplasms
1
Osteosarcoma
1
Neoplasms, Germ Cell and Embryonal
1
Metastatic Digestive System Neuroendocrine Tumor G1
1
Hypertension
1
Gastro-enteropancreatic neuroendocrine tumor
1
Extensive Stage Small Cell Lung Cancer
1
Esthesioneuroblastoma, Olfactory
1
Disease Progression
1
Diffuse Intrinsic Pontine Glioma
1
Central Nervous System Neoplasms
1
Carcinoma
1
Carcinoid Tumor
1
Advanced Lung Neuroendocrine Tumor
1
Adrenal Gland Neoplasms
1
Adrenal Cortex Neoplasms
1
Adenoma, Islet Cell
1
Interventions
pembrolizumab
2
fludarabine
2
durvalumab
2
Pemetrexed
2
Cyclophosphamide
2
Cisplatin
2
130-nm albumin-bound paclitaxel
2
ruxolitinib
1
repotrectinib
1
pralsetinib
1
ponatinib
1
gilteritinib
1
fludarabine phosphate
1
cemiplimab
1
atezolizumab
1
Whole-Body Irradiation
1
Tacrolimus
1
Peripheral Blood Stem Cell Transplantation
1
Patient Reported Outcome Measures
1
Paclitaxel
1
Nivolumab
1
Mycophenolic Acid
1
Mesna
1
Melphalan
1
Immunotherapy
1
Idarubicin
1
Granulocyte Colony-Stimulating Factor
1
Gemcitabine
1
Docetaxel
1
Cytarabine
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Neoplasms by Histologic Type
×
lutetium Lu 177 dotatate
×
90 days
×
Clear all
No trials found.